RU2015132977A - Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболевания - Google Patents
Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболеванияInfo
- Publication number
- RU2015132977A RU2015132977A RU2015132977A RU2015132977A RU2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A RU 2015132977 A RU2015132977 A RU 2015132977A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound
- optionally substituted
- general formula
- group
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 7
- 230000003612 virological effect Effects 0.000 title claims 7
- 230000002265 prevention Effects 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000003446 ligand Substances 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 6
- 206010022000 influenza Diseases 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 229940000425 combination drug Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 3
- 101800004538 Bradykinin Proteins 0.000 claims 3
- 102100031780 Endonuclease Human genes 0.000 claims 3
- 108010042407 Endonucleases Proteins 0.000 claims 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 3
- 102100035792 Kininogen-1 Human genes 0.000 claims 3
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 3
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 3
- 229930003827 cannabinoid Natural products 0.000 claims 3
- 239000003557 cannabinoid Substances 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 241000712891 Arenavirus Species 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- 241000711950 Filoviridae Species 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 claims 2
- 241000713112 Orthobunyavirus Species 0.000 claims 2
- 241000709664 Picornaviridae Species 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750032P | 2013-01-08 | 2013-01-08 | |
| US61/750,032 | 2013-01-08 | ||
| PCT/EP2014/050168 WO2014108408A1 (en) | 2013-01-08 | 2014-01-07 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015132977A true RU2015132977A (ru) | 2017-02-14 |
Family
ID=50073147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015132977A RU2015132977A (ru) | 2013-01-08 | 2014-01-07 | Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболевания |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9199987B2 (enExample) |
| EP (1) | EP2945945B1 (enExample) |
| JP (1) | JP2016504376A (enExample) |
| KR (1) | KR20150103672A (enExample) |
| CN (1) | CN104903319B (enExample) |
| BR (1) | BR112015013414A2 (enExample) |
| CA (1) | CA2894821A1 (enExample) |
| ES (1) | ES2597803T3 (enExample) |
| HK (1) | HK1211288A1 (enExample) |
| MX (1) | MX2015008292A (enExample) |
| RU (1) | RU2015132977A (enExample) |
| WO (1) | WO2014108408A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61381B1 (sr) | 2015-04-28 | 2021-02-26 | Shionogi & Co | Derivat policikličnog piridona protiv gripa i njegov prolek |
| MY189144A (en) | 2015-04-28 | 2022-01-28 | Shionogi & Co | Substituted polycyclic pyridone derivatives and prodrugs thereof |
| HK1254961A1 (en) | 2015-12-15 | 2019-08-02 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JP2020176263A (ja) * | 2019-04-19 | 2020-10-29 | 住友化学株式会社 | フィルム及び農園芸用施設 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| JP4953297B2 (ja) | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| WO2006125048A2 (en) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| WO2009089263A2 (en) * | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
| JP5697163B2 (ja) | 2009-03-26 | 2015-04-08 | 塩野義製薬株式会社 | 置換された３−ヒドロキシ−４−ピリドン誘導体 |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| EP2483275B1 (en) * | 2009-10-01 | 2014-10-15 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
-
2014
- 2014-01-07 US US14/149,381 patent/US9199987B2/en not_active Expired - Fee Related
- 2014-01-07 ES ES14703780.8T patent/ES2597803T3/es active Active
- 2014-01-07 JP JP2015551201A patent/JP2016504376A/ja active Pending
- 2014-01-07 MX MX2015008292A patent/MX2015008292A/es unknown
- 2014-01-07 EP EP14703780.8A patent/EP2945945B1/en not_active Not-in-force
- 2014-01-07 RU RU2015132977A patent/RU2015132977A/ru not_active Application Discontinuation
- 2014-01-07 CN CN201480004147.6A patent/CN104903319B/zh not_active Expired - Fee Related
- 2014-01-07 KR KR1020157016509A patent/KR20150103672A/ko not_active Withdrawn
- 2014-01-07 BR BR112015013414A patent/BR112015013414A2/pt not_active IP Right Cessation
- 2014-01-07 WO PCT/EP2014/050168 patent/WO2014108408A1/en not_active Ceased
- 2014-01-07 HK HK15112100.5A patent/HK1211288A1/xx unknown
- 2014-01-07 CA CA2894821A patent/CA2894821A1/en not_active Abandoned
-
2015
- 2015-10-22 US US14/920,000 patent/US9505758B2/en not_active Expired - Fee Related
-
2016
- 2016-11-28 US US15/361,710 patent/US20170290834A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2945945B1 (en) | 2016-08-31 |
| WO2014108408A1 (en) | 2014-07-17 |
| US20170290834A1 (en) | 2017-10-12 |
| CA2894821A1 (en) | 2014-07-17 |
| JP2016504376A (ja) | 2016-02-12 |
| CN104903319A (zh) | 2015-09-09 |
| US9199987B2 (en) | 2015-12-01 |
| US20160039818A1 (en) | 2016-02-11 |
| HK1211288A1 (en) | 2016-05-20 |
| EP2945945A1 (en) | 2015-11-25 |
| KR20150103672A (ko) | 2015-09-11 |
| ES2597803T3 (es) | 2017-01-23 |
| CN104903319B (zh) | 2017-05-31 |
| US20140194432A1 (en) | 2014-07-10 |
| US9505758B2 (en) | 2016-11-29 |
| BR112015013414A2 (pt) | 2017-07-11 |
| MX2015008292A (es) | 2016-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015125570A (ru) | Пиридоновые производные и их применение в лечении, уменьшении интенсивности симптомов или предотвращении вирусного заболевания | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2016518305A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| RU2014120421A (ru) | Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| RU2015132977A (ru) | Нафтиридиноновые производные и их применение в лечении, уменьшении интенсивности или профилактике вирусного заболевания | |
| JP2015517555A5 (enExample) | ||
| RU2014146778A (ru) | Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания | |
| JP2014530837A5 (enExample) | ||
| RU2014120477A (ru) | Производные пиримидин-4-она и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| JP2016508145A5 (enExample) | ||
| JP2010536887A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| EA201892300A1 (ru) | Макроциклические ингибиторы mcl1 для лечения рака | |
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| JP2016518437A5 (enExample) | ||
| RU2014115796A (ru) | Модуляторы ror-гамма | |
| JP2020532545A5 (enExample) | ||
| JP2019510034A5 (enExample) | ||
| JP2019501879A5 (enExample) | ||
| CN102993148A (zh) | 槲皮素衍生物或其类似物及其应用 | |
| JP2017500295A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180411 |